Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 7/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | BCL2 | P10415 | 3/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097221 | 0.82 | PTGES (0.55) | PTGESMCL1BTKCASRBCL2 | |
| SCHEMBL3571592 | 0.82 | PTGES (0.68) | PTGESDHODHMCL1BCL2MDM2 | |
| SCHEMBL4102890 | 0.78 | EGLN1 (0.42) | DHODHFFAR1 | |
| SCHEMBL4095101 | 0.73 | PTGES (0.55) | PTGESMCL1CASRBCL2MDM2 | |
| SCHEMBL4096031 | 0.72 | PTGES (0.43) | PTGESDHODHMCL1BTKCASR | |
| SCHEMBL4923185 | 0.72 | PTGDR (0.42) | PTGESPOLBADCY1 | |
| SCHEMBL3577805 | 0.71 | PTGES (0.53) | PTGESPOLBMAPTAPP | |
| SCHEMBL4918295 | 0.70 | PTGDR (0.42) | PTGESADCY1 | |
| SCHEMBL3007035 | 0.69 | PTGES (0.48) | PTGESCASRMAPTAPPADCY1 | |
| SCHEMBL3007508 | 0.69 | PTGES (0.47) | PTGESMCL1CASRBCL2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048285-A1 | Pyrrolopyridines Useful in the Treatment of Inflammation | PYCR1, ARG2, ARG1 | PTGES 47/4885DHODH 2403/4885MCL1 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.